Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eglumetad
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LY-354740, also known as eglumetad, is a potent and selective agonist of group II metabotropic glutamate receptors (mGlu2 and mGlu3), with nanomolar EC50 values at these receptors and minimal activity at other mGlu receptor subtypes. It is an analog of glutamate that acts to inhibit excessive glutamate release in the brain, providing anxiolytic, antipsychotic, anti-addictive, and neuroprotective effects in animal models. Clinically, it has been studied for generalized anxiety disorder with efficacy comparable to benzodiazepines but with improved tolerability. LY-354740 has also shown properties in animal models relevant to nicotine withdrawal and panic disorders. It was developed by Eli Lilly for oral administration as a small molecule therapeutic[1][2][4][6][7][10].
- Other names
- LY 354740LY354740LY-354740eglumetad
02
Targets
GRM3 (mGluR3)
Beyond the preview
Go deeper on eglumetad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eglumetad.